Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
Read More
Tag: Gustave Roussy
PARP inhibitors could exploit weaknesses in a range of cancers
Drug type could offer a new approach to treating a number of cancers with PBRM1 mutations
Read More
- Deep Science Ventures and MDC partner to accelerate brain treatments
- Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
- Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
- Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
- KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
